Jason A. Mouabbi: Here are my anticipated Top 3 breast cancer presentations for ASCO24
Jason A. Mouabbi, Breast Medical Oncologist at MD Anderson Cancer Center, shared a post on X:
“Excited for ASCO24! Here are my anticipated Top 3 breast cancer presentations and their importance:
LBA1000: DESTINY-Breast06 – T-DXd vs TPC in HR+, HER2-low/ultralow mBC after ET. Importance Will T-DXd become the preferred first-line agent for endocrine-refractory HR+ mBC? Does HER2-low status still matter?
LBA1001: postMONARCH – Abemaciclib + fulvestrant vs fulvestrant alone for HR+, HER2- advanced BC post CDK4/6i + ET. Importance
Can we use CDK4/6 inhibitors sequentially?
LBA1004: SACI-IO HR+ – Sacituzumab govitecan ± pembrolizumab in metastatic HR+/HER2- BC.
Importance Will immunotherapy finally enter the ER+ mBC space?”
Source: Jason A. Mouabbi/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023